Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.56 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.54 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.54 |
| ▸ | S1PR2 | O95136 | 5/20 | 0.48 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.48 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.48 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.48 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LAP3 | P28838 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | GMNN | O75496 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | THPO | P40225 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29186627 | 0.98 | PLA2G1B (0.57) | OPRM1PLA2G1BPLA2G2AS1PR2S1PR1 | |
| SCHEMBL6281344 | 0.98 | PLA2G1B (0.57) | OPRM1PLA2G1BPLA2G2AS1PR2S1PR1 | |
| SCHEMBL6279840 | 0.98 | PLA2G1B (0.57) | OPRM1PLA2G1BPLA2G2AS1PR2S1PR1 | |
| SCHEMBL24403199 | 0.92 | OPRM1 (0.46) | OPRM1PLA2G1BPLA2G2AS1PR2S1PR1 | |
| SCHEMBL7058526 | 0.92 | OPRM1 (0.46) | OPRM1PLA2G1BPLA2G2AS1PR2S1PR1 | |
| SCHEMBL28977213 | 0.90 | PLA2G1B (0.59) | OPRM1PLA2G1BPLA2G2AS1PR2S1PR1 | |
| SCHEMBL16371002 | 0.90 | PLA2G1B (0.59) | OPRM1PLA2G1BPLA2G2AS1PR2S1PR1 | |
| SCHEMBL21161889 | 0.90 | PLA2G1B (0.59) | OPRM1PLA2G1BPLA2G2AS1PR2S1PR1 | |
| SCHEMBL28446507 | 0.90 | PLA2G1B (0.59) | OPRM1PLA2G1BPLA2G2AS1PR2S1PR1 | |
| SCHEMBL15319803 | 0.90 | PLA2G1B (0.59) | OPRM1PLA2G1BPLA2G2AS1PR2S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220135513-A1 | METHODS OF MANUFACTURING TREPROSTINIL AND TREPROSTINIL DERIVATIVE PRODRUGS | BIOPHARMA CREDIT PLC (GB) | 2022-05-05 | — | — | US | disclosed |
| US-6919291-B2 | Fluorinated zwitterionic cocatalyst activators for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2005-07-19 | — | — | US | disclosed |
| US-20040110631-A1 | Fluorinated zwitterionic cocatalyst activators for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2004-06-10 | — | — | US | disclosed |
| EP-1349653-A2 | FLUORINATED ZWITTERIONIC COCATALYST ACTIVATORS FOR OLEFIN POLYMERIZATION | ExxonMobil Chemical Patents Inc. (US) | 2003-10-08 | — | — | EP | disclosed |
| EP-0994108-B1 | PROCESS FOR PRODUCING 2-HYDROXYBENZAMIDE DERIVATIVES | ZERIA PHARM CO LTD (JP) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002036639-A2 | FLUORINATED ZWITTERIONIC COCATALYST ACTIVATORS FOR OLEFIN POLYMERIZATION | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2002-05-10 | — | — | WO | disclosed |
| US-6197970-B1 | REACTING WITH SECONDARY OR TERTIARY AMINE; DEBLOCKING, DEPROTECTING | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2001-03-06 | — | — | US | disclosed |
| EP-0994108-A1 | PROCESS FOR PRODUCING 2-HYDROXYBENZAMIDE DERIVATIVES | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135513-A1 | METHODS OF MANUFACTURING TREPROSTINIL AND TREPROSTINIL DERIVATIVE PRODRUGS | PTGIS, PTGER1, PTGIR | OPRM1 2769/4885PLA2G1B 515/4885PLA2G2A 693/4885 |
| US-20040110631-A1 | Fluorinated zwitterionic cocatalyst activators for olefin polymerization | FZD7, FOS, COG4 | OPRM1 59/4885PLA2G1B 1285/4885PLA2G2A 825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.